Acrylamide analog as a novel nitric oxide-independent soluble guanylyl cyclase activator

Journal of Pharmacological Sciences

Volumn 102, Issue 2, 2006, Pages 231-238

  Nakane, Masaki ^a   Kolasa, Teodozyi ^a   Chang, Renjie ^a   Miller, Loan N ^a   Moreland, Robert B ^a   Brioni, Jorge D ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Activator; Nitric oxide; Sodium nitroprusside; Soluble guanylyl cyclase; YC 1

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 3 [2 (4 CHLOROPHENYLTHIO)PHENYL] N (4 DIMETHYLAMINOBUTYL)ACRYLAMIDE; 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDIN 4 YLAMINE; A 778935; ACRYLAMIDE DERIVATIVE; BAY 418543; CYCLIC GMP; GUANYLATE CYCLASE ACTIVATOR; GUANYLATE CYCLASE INHIBITOR; NITRIC OXIDE; NITROPRUSSIDE SODIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG IDENTIFICATION; DRUG INHIBITION; DRUG STRUCTURE; NONHUMAN; SMOOTH MUSCLE FIBER;

EID: 33750612237     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FPJ06017X     Document Type: Article

References (45)

1. Murad F. The 1996 Albert Lasker Medical Research Awards. Signal transduction using nitric oxide and cyclic guanosine monophosphate. JAMA. 1996;276:1189-1192.
2. Davis KL, Martin E, Turko IV, Murad F. Novel effects of nitric oxide. Annu Rev Pharmacol Toxicol. 2001;41:203-236.
3. Brioni JD, Nakane M, Hsieh GC, Moreland RB, Kolasa T, Sullivan JP. Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res. 2002;14:8-14.
4. Bult H, Herman AG, Matthys KE. Antiatherosclerotic activity of drugs in relation to nitric oxide function. Eur J Pharmacol. 1999;375:157-176.
5. Janero DR. Nitric oxide (NO)-related pharmaceuticals: contemporary approaches to therapeutic NO modulation. Free Radic Biol Med. 2000;28:1495-1506.
6. Moreland RB, Hsieh G, Nakane M, Brioni JD. The biochemical and neurologic basis for the treatment of male erectile dysfunction. J Pharmacol Exp Ther. 2001;296:225-234.
7. Kamisaki Y, Saheki S, Nakane M, Palmieri JA, Kuno T, Chang BY, et al. Soluble guanylate cyclase from rat lung exists as a heterodimer. J Biol Chem. 1986;261:7236-7241.
8. Nakane M, Murad F. Cloning of guanylyl cyclase isoforms. Adv Pharmacol. 1994;26:7-18.
9. Buechler WA, Nakane M, Murad F. Expression of soluble guanylate cyclase activity requires both enzyme subunits. Biochem Biophys Res Commun. 1991;174:351-357.
10. Nakane M, Arai K, Saheki S, Kuno T, Buechler W, Murad F. Molecular cloning and expression of cDNAs coding for soluble guanylate cyclase from rat lung. J Biol Chem. 1990;265:16841-16845.
11. Foerster J, Harteneck C, Malkewitz J, Schultz G, Koesling D. A functional heme-binding site of soluble guanylyl cyclase requires intact N-termini of alpha 1 and beta 1 subunits. Eur J Biochem. 1996;240:380-386.
12. Ignarro LJ, Degnan JN, Baricos WH, Kadowitz PJ, Wolin MS. Activation of purified guanylate cyclase by nitric oxide requires heme. Comparison of heme-deficient, heme-reconstituted and heme-containing forms of soluble enzyme from bovine lung. Biochim Biophys Acta. 1982;718:49-59.
13. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, Mayer B. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol. 1995;48:184-188.
14. Schrammel A, Behrends S, Schmidt K, Koesling D, Mayer B. Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol. 1996;50:1-5.
15. Wu CC, Ko FN, Kuo SC, Lee FY, Teng CM. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol. 1995;116:1973-1978.
16. Friebe A, Schultz G, Koesling D. Stimulation of soluble guanylate cyclase by superoxide dismutase is mediated by NO. Biochem J. 1998;335:527-531.
17. Stone JR, Marletta MA. Synergistic activation of soluble guanylate cyclase by YC-1 and carbon monoxide: implications for the role of cleavage of the iron-histidine bond during activation by nitric oxide. Chem Biol. 1998;5:255-261.
18. Margulis A, Sitaramayya A. Rate of deactivation of nitric oxide-stimulated soluble guanylate cyclase: influence of nitric oxide scavengers and calcium. Biochemistry. 2000;39:1034-1039.
19. Martin E, Lee YC, Murad F. YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components. Proc Natl Acad Sci U S A. 2001;98:12938-12942.
20. Koglin M, Behrends S. A functional domain of the alpha1 subunit of soluble guanylyl cyclase is necessary for activation of the enzyme by nitric oxide and YC-1 but is not involved in heme binding. J Biol Chem. 2003;278:12590-12597.
21. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, et al. NO-independent regulatory site on soluble guanylate cyclase. Nature. 2001;410:212-215.
22. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, et al. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol. 2002;136:773-783.
23. Selwood DL, Brummell DG, Budworth J, Burtin GE, Campbell RO, Chana SS, et al. Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase. J Med Chem. 2001;44:78-93.
24. Kolasa T, Patel M, Bhatia P, Rohde J, Zhang Q, Zhiren X, et al. Ortho-substituted arylalkyl (alkenyl)-carboxylic acid amide as activators of soluble guanylate cyclase. Drugs Future. 2002;27:305.
25. Miller LN, Nakane M, Hsieh GC, Chang R, Kolasa T, Moreland RB, et al. A-350619: a novel activator of soluble guanylyl cyclase. Life Sci. 2003;72:1015-1025.
26. Nakane M, Saheki S, Kuno T, Ishii K, Murad F. Molecular cloning of a cDNA coding for 70 kilodalton subunit of soluble guanylate cyclase from rat lung. Biochem Biophys Res Commun. 1988;157:1139-1147.
27. O'Reilly DR. Use of baculovirus expression vectors. Methods Mol Biol. 1997;62:235-246.
28. Hoenicka M, Becker EM, Apeler H, Sirichoke T, Schroder H, Gerzer R, et al. Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide. J Mol Med. 1999;77:14-23.
29. Martin E, Sharina I, Kots A, Murad F. A constitutively activated mutant of human soluble guanylyl cyclase (sGC): implication for the mechanism of sGC activation. Proc Natl Acad Sci U S A. 2003;100:9208-9213.
30. Gupta S, Moreland R, Yang S, Gallant C, Goldstein I, Traish A. The expression of functional postsynaptic alpha2-adrenoceptors in the corpus cavernosum smooth muscle. Br J Pharmacol. 1998;123:1237-1245.
31. Stasch JP, Dembowsky K, Perzborn E, Stahl E, Schramm M. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br J Pharmacol. 2002;135:344-355.
32. Hussain AS, Marks GS, Brien JF, Nakatsu K. The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-alpha] quinoxalin-1-one (ODQ) inhibits relaxation of rabbit aortic rings induced by carbon monoxide, nitric oxide, and glyceryl trinitrate. Can J Physiol Pharmacol. 1997;75:1034-1037.
33. Zhao Y, Brandish PE, DiValentin M, Schelvis JP, Babcock GT, Marletta MA. Inhibition of soluble guanylate cyclase by ODQ. Biochemistry. 2000;39:10848-10854.
34. Friebe A, Koesling D. Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol Pharmacol. 1998;53:123-127.
35. Wegener JW, Closs EI, Forstermann U, Nawrath H. Failure of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) to inhibit soluble guanylyl cyclase in rat ventricular cardiomyocytes. Br J Pharmacol. 1999;127:693-700.
36. Straub A, Stasch JP, Alonso-Alija C, Benet-Buchholz J, Ducke B, Feurer A, et al. NO-independent stimulators of soluble guanylate cyclase. Bioorg Med Chem Lett. 2001;11:781-784.
37. Stasch JP, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Minuth T, et al. Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br J Pharmacol. 2002;135:333-343.
38. Moreland RB, Hsieh G, Nakane M, Miller LN, Chang R, Kolasa T, et al. Novel soluble guanylate cyclase activators A-344905 and A-350619 activate sGC in vitro and facilitate erection in rats. J Urol. 2002;167:239 (Abstract 938).
39. Friebe A, Koesling D. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res. 2003;93:96-105.
40. Schmidt P, Schramm M, Schroder H, Stasch JP. Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase. Eur J Pharmacol. 2003;468:167-174.
41. Balashova N, Chang FJ, Lamothe M, Sun Q, Beuve A. Characterization of a novel type of endogenous activator of soluble guanylyl cyclase. J Biol Chem. 2005;280:2186-2196.
42. Linder AE, Leite R, Lauria K, Mills TM, Webb RC. Penile erection requires the association of soluble guanylyl cyclase with endothelial caveolin-1 in rat corpus cavernosum. Am J Physiol Regul Integr Comp Physiol. 2005;22:22.
43. Nakane M, Hsieh G, Miller LN, Chang R, Terranova MA, Moreland RB, et al. Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1. Int J Impot Res. 2002;14:121-127.
44. Hsieh GC, O'Neill AB, Moreland RB, Sullivan JP, Brioni JD. YC-1 potentiates the nitric oxide /cyclic GMP pathway in corpus cavernosum and facilitates penile erection in rats. Eur J Pharmacol. 2003;458:183-189.
45. Mizusawa H, Hedlund P, Brioni JD, Sullivan JP, Andersson KE. Nitric oxide independent activation of guanylate cyclase by YC-1 causes erectile responses in the rat. J Urol. 2002;167:2276-2281.